June 14, 2017
Today, Tom talks with bioethicist Dr. Jeffrey Kahn about clinical trials and diversity. Why is so much medical research still done with white subjects — and more often with men rather than women — and what are the consequences of that, particularly for women and people of color?
If clinical trials are done by examining only parts of our society, what does that mean for the efficacy of the findings, and how reliably can those results be extrapolated to apply to the rest of the population?
And what are the consequences when that research is then used to develop treatments? Will they be effective for everyone, or primarily just for the group at the heart of the research?
To wit: African Americans have a far greater incidence of Alzheimer’s Disease and a far lower rate of inclusion in clinical trials. What, if any, is the connection between those two realities?
Dr. Jeffrey Kahn is the Director of the Johns Hopkins Berman Institute of Bioethics and he stops by Midday from time to time to talk about how ethicists help us frame complex questions like these.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.